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Abstract
Peri-partum cardiomyopathy (PPCM) is a frequently fatal disease that affects women near
delivery, and occurs more frequently in women with pre-eclampsia and/or multiple gestation. The
etiology of PPCM, or why it associates with pre-eclampsia, remains unknown. We show here that
PPCM is associated with a systemic angiogenic imbalance, accentuated by pre-eclampsia. Mice
that lack cardiac PGC-1α, a powerful regulator of angiogenesis, develop profound PPCM.
Importantly, the PPCM is entirely rescued by pro-angiogenic therapies. In humans, the placenta in
late gestation secretes VEGF inhibitors like soluble Flt1 (sFlt1), and this is accentuated by
multiple gestation and pre-eclampsia. This anti-angiogenic environment is accompanied by sub-
clinical cardiac dysfunction, the extent of which correlates with circulating levels of sFlt1.
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tExogenous sFlt1 alone caused diastolic dysfunction in wildtype mice, and profound systolic
dysfunction in mice lacking cardiac PGC-1α. Finally, plasma samples from women with PPCM
contained abnormally high levels of sFlt1. These data strongly suggest that PPCM is in large part a
vascular disease, caused by excess anti-angiogenic signaling in the peri-partum period. The data
also explain how late pregnancy poses a threat to cardiac homeostasis, and why pre-eclampsia and
multiple gestation are important risk factors for the development of PPCM.
PPCM affects 1:300 to 1: 3000 pregnancies, with geographic hot spots like Nigeria and
Haiti.1,2 The disease is characterized by systolic heart failure presenting in the last month of
pregnancy or the 1st 4 months post-partum. Although approximately half of affected women
recover cardiac function post-partum, many women progress to chronic heart failure, cardiac
transplantation, or death. PPCM can thus devastate otherwise healthy young women and
their infants. PPCM remains an orphan disease of unknown etiology. The onset late in
gestation does not coincide with increased hemodynamic load on the heart, suggesting other
mechanisms. Recent data has suggested that anti-angiogenic prolactin fragments may play
an important role in some patients.3 Risk factors for PPCM also include pre-eclampsia and
multiple gestation, suggesting potential mechanistic overlap with these processes.1,2
PGC-1α is a transcriptional coactivator that drives mitochondrial biogenesis and other
metabolic programs in numerous tissues, including the heart.4,5 PGC-1α is highly expressed
in the heart, and mice lacking PGC-1α globally have abnormal cardiac energetic reserves
and respond poorly to stressful stimuli such as transverse aortic banding.6,7 In addition to its
role in mitochondrial homeostasis, PGC-1α also induces the expression and secretion of
pro-angiogenic factors such as vascular endothelial growth factor (VEGF) that leads to
formation of new blood vessels.8,9 While the angiogenic function of PGC-1α has been
described in skeletal muscle, its role in cardiac tissue remains unexplored.
Cardiac-specific PGC-1α deletion leads to PPCM
To further study the role of PGC-1α in the heart, we generated cardiac-specific PGC-1α
knock-out (HKO) mice (see materials and methods). While studying these mice, we noticed
that female HKO mice were fertile, and delivered normal litter sizes (not shown), but
invariably died after 1 or 2 pregnancies (Figure 1a). The hearts of these mice were large,
dilated, and fibrotic (Figure 1b–d), consistent with a dilated cardiomyopathy. 2-dimensional
M-mode echocardiography revealed dilated, poorly contractile hearts in HKO mice after
their 2nd delivery (Figure 1e). Left ventricular end-diastolic and end-systolic dimensions
(LVEDD and LVESD) were markedly enlarged, and fractional shortening (FS), a direct
measure of cardiac contractile function, was profoundly depressed (Figure 1f–i). Nulliparous
mice, as well as post-partum control mice, were not affected. Males were also not affected
(Figure S1). The absence of PGC-1α in cardiomyocytes thus leads to a profound PPCM in
mice.
PGC-1α regulates angiogenesis in cardiac tissue
We have recently shown in skeletal muscle that PGC-1α regulates angiogenesis by driving
the expression of angiogenic factors like VEGF.8,9 Anti-angiogenic therapies, including
antibodies that neutralize VEGF and small molecule VEGF receptor inhibitors, are being
increasingly used in the oncological and ophthalmological settings, and cardiomyopathy and
heart failure have recently been recognized as important side effects10,11, demonstrating that
anti-angiogenic therapy can be harmful to the heart in humans. Impaired VEGF signaling
has also been linked with cardiac dysfunction in mice.12,13 At the same time, late pregnancy
is a strong anti-angiogenic environment, in part due to the secretion by the placenta of anti-
angiogenic factors like sFlt1 that bind to and neutralize soluble members of the VEGF
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tfamily.14 These observations led us to postulate that PGC-1α regulates an angiogenic
program in cardiomyocytes, and that the absence of this program would leave the hearts
defenseless to the anti-angiogenic setting of late pregnancy, thus leading the animals to
develop PPCM.
Consistent with the above notion, over-expression of PGC-1α in neonatal rat ventricular
myocytes (NRVMs) strongly induced angiogenic genes involved in the activation and
recruitment of endothelial cells (e.g., vegfa) and mural cells (e.g., pdgfb), along with, as
previously shown15, genes involved in the mitochondrial respiratory chain (cycs, cox5b)
(Figure 2a). Interestingly, some angiogenic genes were repressed (e.g., bfgf), a pattern
similar to that seen in skeletal muscle cells8, indicating that PGC-1α reprograms the
angiogenic program in a stereotypical manner. Conversely, siPGC-1α significantly
suppressed the expression of vegfa (Figure 2b). Endothelial activation and migration is a
hallmark of angiogenesis. As shown in Figure 2c–d, over-expression of PGC-1α in NRVMs
led to a dramatic, dose-dependent, up to six-fold increase in the migration of the adjacent
human vein endothelial cells (HUVECs) in a co-culture system. Addition of sFlt1
completely neutralized the induced endothelial migration, indicating that secreted members
of the VEGF family, likely vegfa itself, are critical for the effect. Conversely, repression of
PGC-1α in NRVMs by siRNA significantly repressed endothelial migration (Figure 2e).
PGC-1α thus controls an angiogenic program in cardiomyocytes.
To test if PGC-1α is required for this program in intact animals, levels of vegfa and other
angiogenic factors were measured in hearts from PGC-1α HKO mice. As shown in Figure
3a, the expression of vegfa and pdgfb, and a number of other angiogenic factors, was
repressed in these hearts by as much as 50%. VEGFA protein was decreased by 30% in
HKO hearts (Figure 3b). Levels of VEGFA are normally tightly regulated, and even global
haplo-insufficiency is lethal16,17, underscoring the significance of a 30% drop in protein
levels. Consistent with these findings, the capillary density of HKO hearts, as measured by
staining with the endothelial-specific marker CD31, was decreased by about 15% (Figure
3c–d). PGC-1α thus regulates both vascular density (these data) and mitochondrial
function18 in the heart, providing an important regulatory link between the delivery of fuel
(blood vessels), and its consumption (mitochondria). These data suggested that PPCM in
these mice might be caused by the combination of a heart-specific vascular defect caused by
the absence of PGC-1α, and the normal systemic anti-angiogenic environment of late
pregnancy. Indeed, the vascular density in HKO hearts decreased by almost 50% post-
partum (Figure 3c–d), equivalent to that seen in mice lacking cardiac VEGF.19 Consistent
with this vascular rarefaction, perfusion of post-partum HKO hearts was profoundly
decreased nearly 50% compared to wild type animals, as determined by MIBI uptake and
SPECT/CT (Figure 3e–f).
Pro-angiogenic therapy rescues PPCM
To test directly the notion that an angiogenic imbalance drives PPCM in HKO mice, rescue
experiments were done. In a first series of experiments, breeding mice were administered
daily subcutaneous injections of VEGF-121 protein (100mcg/kg), versus vehicle control
(Figure S2). The efficacy of VEGF-121 injections was confirmed by the presence of
VEGF-121 in the serum, and robust activation of cardiac VEGFR2 phosphorylation within
30 minutes of injection (Figure S2b–c). The VEGF treatment led to improved survival of the
breeding HKO females, up to five pregnancies (Figure S2d). However, capillary density was
only partly rescued, cardiac contractility was only marginally improved, and the hearts
remained quite enlarged (Figure S2e–g). VEGF administration thus partly rescued lethality
in multiparous HKO animals, but was insufficient to fully rescue PPCM, suggesting that
other pathways are also important.
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tHilfiker-Kleiner et al. recently showed that STAT3 regulates mitochondrial superoxide
dismutase (MnSOD) and protects against reactive oxygen species (ROS) in the heart.3
Absence of cardiac STAT3 and the consequent increase in ROS led to inappropriate
cleavage of prolactin to a potent anti-angiogenic 16kda form, and subsequent PPCM (Figure
4a). Importantly, the PPCM could be rescued by treatment with bromocriptine, which
inhibits the secretion of prolactin from the pituitary gland. PGC-1α is known to increase
ROS scavenging.20 In cardiomyocytes, over-expression of PGC-1α strongly induced
MnSOD mRNA expression and protein (Figure S3a–b). Conversely, MnSOD was repressed
in PGC-1α HKO hearts, and levels of reactive oxygen species (ROS) were increased (Figure
S3c–d). PGC-1α and STAT3 thus both regulate MnSOD and ROS in cardiomyocytes,
suggesting that the absence of PGC-1α in the heart may, like the absence of STAT3, lead to
prolactin-mediated anti-angiogenic effects. Prolactin had no direct effects on PGC-1α or
VEGF expression in cardiac cells, and prolactin levels did not differ in heart or serum
between wild-type and HKO animals (Figure S4).
These observations thus suggested that PGC-1α regulates two separate pro-angiogenic
pathways in the heart, a VEGF pathway and a prolactin pathway, and that aberration of both
pathways in PGC-1α HKO mice leads to PPCM (Figure 4a). To test this idea directly, both
pathways were rescued simultaneously: breeding HKO mice were treated with daily
subcutaneous injections of VEGF protein and with bromocriptine supplementation in the
water (Figure 4b). This double treatment resulted in complete rescue of the PPCM in HKO
females (Figure 4c). After two pregnancies, heart weights and all echocardiographic indices
of cardiac function (FS, LVEDD, LVESD) were normal in HKO mice (Figure 4c–h).
Bromocriptine alone prevented some of the LV dilation, but provided only minimal rescue
of LV function, demonstrating that rescue of both pathways is necessary (Figure 4c–h).
Together, these data indicate that PPCM can be caused by an angiogenic imbalance and
vascular dysfunction, at least in rodents.
Pre-eclampsia and cardiac dysfunction
To test the idea that anti-angiogenic signaling can cause cardiac dysfunction in pregnant
women, studies were undertaken with women with pre-eclampsia, in whom VEGF signaling
is compromised due to high serum levels of anti-angiogenic sFlt1.21 (see Supplementary
Table 1 for patient characteristics). Cardiac function was evaluated non-invasively by
measuring myocardial performance index (MPI, or Tei index) and other indices of cardiac
function with cardiac echocardiography. MPI measures the relative duration of isovolemic
contraction and relaxation (Figure 5a), and is a sensitive marker of diastolic function.22–24
Women with pre-eclampsia had markedly increased serum levels of sFlt1 (Figure S5a,
p=0.005), as previously shown.21 Strikingly, women with pre-eclampsia also had markedly
abnormal MPI (Figure 5b and Supplementary Table 2, p=0.01) and E/E′ (Figure 5c and
Supplementary Table 2, p=0.02), another sensitive measure of cardiac dysfunction.25
Moreover, the MPI correlated with levels of circulating sFlt1 (Figure 5d, R=0.59, p=0.003).
Elevated blood pressure (BP) in the pre-eclamptic women (Supplementary Table 1) is
unlikely to explain the worsening MPI, because MPI is thought to reflect cardiac function
independently of BP22, and pregnant women with similar mild elevations of BP but without
pre-eclampsia have normal cardiac function.26 Instead, these data suggested that elevated
sFlt1 causes the diastolic dysfunction. To test this hypothesis directly, sFlt1 was delivered
systemically to pregnant mice by intravenous injection of adenoviruses expressing sFlt1, and
MPI was examined using high-resolution murine echocardiography. sFlt1 caused significant
increases in MPI in these mice within 10 days (Figure 5e). These data, taken together with
published observations in patients receiving anti-angiogenic therapies10,11, thus strongly
suggest that elevated sFlt1 causes cardiac dysfunction in women with pre-eclampsia. While
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tthe LV dysfunction recovers following delivery in many patients, a second insult in some
women likely precipitates PPCM.
sFlt1 induces cardiomyopathy and is high in PPCM
The above observations strongly support the hypothesis that PPCM can be induced by
excess anti-angiogenic signaling, including the high expression of sFlt1 during late gestation
seen in both women27 and mice (Figure S5c, p=.009). To test this hypothesis directly, sFlt1
was delivered systemically to nulliparous mice, as above. PGC-1α HKO mice that received
sFlt1 developed profound cardiac failure within three weeks, as evidenced by increases in
cardiac weight and dramatic decreases in fractional shortening on echocardiography (Figure
6a–c). This was accompanied by a striking drop in vascular density (Figure S6), though not
in larger vessels (Figure S7). Wild-type mice also revealed significant, though less
extensive, decreases in vascular density and cardiac function after exposure to three weeks
of sFlt1. sFlt1 alone is thus sufficient, even in the absence of pregnancy, to cause dramatic
cardiomyopathy in the setting of a heart unable to withstand the anti-angiogenic insult.
To further investigate in humans if elevated sFlt1 levels could be contributing to PPCM,
plasma from women with PPCM was acquired 4–6wks post-partum and sFlt1 levels were
measured. sFlt1 levels normally return to normal within 48–72hrs after delivery.28 sFlt1
levels were elevated in a large subset of these PPCM patients (p=0.002), remaining up to 5-
or 10-fold higher than the levels in control participants (Figure 6d). Post-partum sFlt1 levels
can remain modestly higher in subjects with pre-eclampsia29,30, but the levels found here are
notably higher. The findings are thus consistent with the notion that a significant percentage
of PPCM subjects have been exposed to pre-eclampsia, and that secretion of sFlt1 persists
inappropriately post-partum. Indeed, in our own institution, 33% of the last 75 cases of
PPCM were associated with pre-eclampsia (Figure 6e–f), markedly more than the
population rate of 3–5%.31 The persisting extra-placental source of sFlt1 in the post-partum
period is not known, and may include placental remnants, circulating mononuclear cells32,
or shed syncytial microparticles33.
Discussion
Our study shows that angiogenic imbalance in the heart during the peri-partum period may
lead to PPCM in mice and in humans. The data strongly suggest that PPCM is caused by a
“two-hit” combination of 1) systemic anti-angiogenic signals during late pregnancy, and 2) a
host susceptibility marked by insufficient local pro-angiogenic defenses in the heart. The
first hit explains why PPCM is a disease of the late gestational period, which is precisely
when circulating anti-angiogenic factors such as sFlt1 peak in pregnancy.21,34 Other
pathways, such as prolactin or excess angiotensina II signaling, may also be involved.3,35
The first hit is also worse in pre-eclampsia, which is characterized by markedly elevated
sFlt1 levels. Associations between pre-eclampsia and PPCM have been well noted in many
populations1,2,36–41 (detailed in Supplementary Table 3). Interestingly, some studies
involving women of African descent have not found an association between hypertensive
disorders of pregnancy and PPCM42, suggesting ethnic variability in the pathogenesis of
PPCM. It is also quite possible that PPCM with and without associated pre-eclampsia have
different pathogeneses.43 Overall, our data strongly indicate that elevated sFlt1 levels in pre-
eclampsia contribute to at least the PPCM that is associated with pre-eclampsia. We further
propose that elevated sFlt1 levels in fact present a challenge to the myocardium in all
pregnancies, thus explaining why the peri-partum period puts women at risk of developing
heart failure, even in the absence of pre-eclampsia. Interestingly, other situations of elevated
sFlt1 (twin pregnancies44) and recurrent exposures to sFlt1 (multiple pregnancies) are also
strong risk factors for PPCM even in the absence of pre-eclampsia.2,43
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existence of a second “hit”. Abnormal PGC-1α function is such an event in rodents, and
may be so in humans as well. A number of previously identified processes may also
constitute this second hit, including myocarditis, immune activation, viral infection, and/or
autoantibodies.43 Interestingly, PGC-1α expression is repressed by inflammatory states in
the heart and elsewhere45,46, suggesting that many of the above processes implicated in
PPCM may in part converge on PGC-1α. Consistent with this, we found repressed PGC-1α
expression in cardiac samples from women with PPCM (Figure S8). Abnormal STAT3
function and ROS production may also contribute3, as may genetic predispositions.47
In conclusion, the data presented here strongly support the idea that PPCM is in part a two-
hit vascular disease due to imbalances in angiogenic signaling, and that anti-angiogenic
states such as pre-eclampsia or multiple gestation significantly worsen the process. Our data
may explain why pregnancy triggers PPCM, and also explain the longstanding
epidemiological observation that pre-eclampsia is a risk factor for developing PPCM. Pro-
angiogenic therapies such as exogenous VEGF-121, or removal of sFlt1 itself48, may thus
be beneficial in PPCM.
METHODS SUMMARY
All animal experiments were performed according to procedures approved by the
Institutional Animal Care and Use Committee. Human soluble VEGF-121 was a kind gift of
Scios, Inc CA. Bromocriptine treatments were done as previously described.3 Human
studies were approved by the institutional review board of Beth Israel Deaconess Medical
Center. Informed consent was obtained from all subjects. Angiogenic factor assays were
performed with commercially available ELISAs (R&D systems, Minneapolis, MN).
Full methods and any associated references are available in the online version of the paper at
www.nature.com
FULL METHODS
Animal studies
All animal experiments were performed according to procedures approved by the
Institutional Animal Care and Use Committee. Mice bearing floxed alleles of PGC-1α
flanking exons 3–4, and mice containing the α-MHC::CRE transgene were kind gifts of
Bruce Spiegelman49 and Mike Schneider50, respectively. Mice were maintained on a
standard rodent chow diet with twelve-hour light and dark cycles. Mice bearing floxed
alleles of PGC-1α flanking exons 3–4, and mice containing the α-MHC::CRE transgene
were kind gifts of Bruce Spiegelman49 and Mike Schneider50, respectively. For murine
echocardiography, the chest hair was removed with a topical depilatory agent, and two-
dimensional images were visualized using a Vivid FiVe echocardiography system (GE
Medical Systems, Milwaukee, Wisconsin, USA) on unanesthetized mice. Parasternal short-
axis projections were visualized, and M-mode recordings at the mid-ventricular level were
recorded. Heart rate, left ventricular end-diastolic and end-systolic (LVEDD, LVESD) were
measured in at least three beats from at least 3 recordings and averaged, and LV fractional
shortening was then calculated (FS = (LVEDD−LVESD)/LVEDD). For the high-resolution
MPI studies, a VisualSonics 2100 echocardiography machine was used on mice anesthetized
with isoflurane, and the MPI was calculated using the manufacturer software program.
SPECT/CT imaging of mice was performed by the Longwood Area Small Animal Imaging
Facility (SAIF). For the VEGF treatment studies, human VEGF-121 (100mcg/kg) was
injected subcutaneously daily, versus saline control. For the bromocriptine studies,
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tbromocriptine was added to the drinking water. Mice were bred starting at the age of 8 wks
while receiving bromocriptine in the drinking water, daily subcutaneous VEGF-121, or both.
Cells and reagents
All reagents were from Sigma, unless otherwise indicated. Human soluble VEGF-121 was a
kind gift of Scios, Inc CA. Staining of capillaries was performed using anti-CD31 antibody
(BD Pharmingen, CA) or isolectin B4 (Vector Lab). Quantification of capillaries was
performed computationally, using Volocity software (Improvision, PerkinElmer), on three
random fields chosen from the septum of transverse sections from the mid-heart. Staining of
arterioles was performed using anti-SMA antibody (Santa Cruz) and quantified similarly,
using random low-power fields. All quantifications were performed blindly. Isolation and
culture of primary neonatal rat ventricular myocytes (NRVMs) was performed as described.
Cells were infected with adenovirus at a multiplicity of infection of 10–30, and mRNA
expression was measured 24 or 48hrs later. The adenovirus expressing PGC-1α51 and
sFlt152 have been described. Prolactin, VEGF, and sFlt1 ELISAs were from R&D Systems.
The thiobarbituic acid reactive substances (TBARS) assay was performed on cardiac
extracts according to manufacturer instructions (Cayman).
Gene expression studies
Total RNA’s were isolated from mouse tissue or cultured cells using the Trizol method
(Invitrogen). Samples for real-time PCR analyses were reverse transcribed (Invitrogen), and
quantitative real-time PCR reactions were performed on the cDNAs in the presence of
fluorescent dye (SYBR green), on a BioRad CFX 384 Touch™ Real-Time PCR Detection
System. DNA product of the expected size was confirmed for each primer pair.
Endothelial migration assay
NRVMs in 24-well plates were infected with adenovirus expressing GFP or PGC-1α for
34hrs. BSA or soluble Flt1 (100ng/ml) was added to the media for 12hrs. Then, 5 × 104 cells
of human umbilical cord endothelial cells (HUVECs) at 5 × 104 were put on the upper
compartment of transwells (8.0um pore size, Corning #3422) pre-warmed with EBM2 media
for O/N at 37°C. HUVEC migration to the lower compartment of transwells was measured
after 12hrs. Migrated HUVECs were fixed with 4% paraformaldehyde in PBS for 20min at
RT, cells remained on the upper compartment were removed with cotton swab. Cells were
blocked with 5% BSA in PBST (0.2% Tween) and stained with phallodin-FITC in PBST for
4hrs to visualize filamentous actin. Transwell inserts were washed three times in PBST and
mounted unto slides with DAPI mounting medium.
Human studies
The institutional review board of Beth Israel Deaconess Medical Center in Boston approved
this study. Eligible women were enrolled after providing written informed consent from
November 2009 through May 2010. Pregnant women at least 18 years of age with a
singleton pregnancy of at least 24 weeks and less than 41 weeks and either a diagnosis of
pre-eclampsia or without any hypertensive disorder of pregnancy were eligible. Exclusion
criteria included pre-existing cardiovascular disease, pulmonary disease and non-gestational
diabetes mellitus. Participants were recruited upon admission to labor and delivery, the ante-
partum floor, or during a routine prenatal visit. All clinical data was abstracted from medical
records. The diagnosis of pre-eclampsia was based on the National High Blood Pressure
Education Program Working Group definition, also endorsed by the American Congress of
Obstetricians and Gynecologists (ACOG). A Maternal-Fetal Medicine specialist confirmed
all diagnoses. Archived plasma samples from subjects with PPCM have been previously
described.3 Patients in both studies were predominantly Caucasian. Retrospective analyses
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tof PPCM and pre-eclampsia in the Harvard teaching hospitals were performed using the
Harvard Shared Health Research Information Network (SHRINE)53, a de-identified
repository of aggregate patient information.
Human echocardiography
Bedside transthoracic echocardiogram was performed using a Siemens X-300
(Mountainview, CA) machine by two expert echocardiographers using P5-1 Transducer.
Images were obtained with the patient lying in the left lateral decubitus position and
reported according to the American Society of Echocardiography guidelines. Images were
stored in a cine-loop format with three cardiac cycles of non- compressed data with
electrocardiogram information. The echocardiographers performed a comprehensive
examination, which included a complete two-dimensional and color flow-Doppler
assessment of the left ventricle, right ventricle and intra-cardiac valves. Specifically: a)
Ejection Fraction: Visual quantitative estimation; b) Trans-mitral pulse wave Doppler (E and
A waves and deceleration time); c) Doppler Tissue Image (DTI): Both medial and lateral
mitral annulus were interrogated, final value of peak velocity of E′ was calculated as
average of three velocities at each location; d) MPI: The MPI calculation was performed off-
line utilizing a Siemens Syngo DICOM viewing station (Mountainview, CA). The
echocardiograms were de-identified before calculating MPI. Ejection fraction, MPI and E/E′
ratios were calculated. Each images was analyzed by one of two blinded
echocardiographers.
Angiogenic factor assays
Women were consented for a blood draw at the time of the echocardiogram. All samples for
the MPI study were collected in the ante-partum prior to the delivery, while samples in the
PPCM study were collected 4–6wks post-partum. The samples were centrifuged at 3000
RPM for 8 minutes and plasma was collected and stored at −80° C. Samples were randomly
ordered and analyzed by a single person in a blinded fashion. ELISAs for sFlt1 were
performed with commercially available kits (R&D systems, Minneapolis, MN). All assays
were performed in duplicate and values were averaged. If >20% difference was observed
between duplicate values, the samples were reanalyzed.
Data and statistical analysis
SAS 9.2 (SAS institute Inc., Cary, NC) was used for data analysis. All tests were two sided,
and P values <0.05 were considered statistically significant. Data are presented as mean +/−
standard error, or median and inter-quartile ranges, as indicated. Comparisons were made
using two-tailed Student’s t-test or non-parametric Mann-Whitney test, as indicated.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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tFigure 1. Mice lacking cardiac PGC-1α develop peri-partum cardiomyopathy
a, Kaplan-Meier survival curve in female αMHC-Cre: PGC-1αlox/lox mice (F HKO), versus
HKO males or control mice of either gender (M/F CT). b, Hematoxylin and Eosin and
Masson Trichrome stains of hearts from post-partum HKO mice (PP HKO), versus CT mice
(PP CT). c–d, Heart weight (c) and heart weight/tibial length ratios (d) of nulliparous CT
and HKO mice, and after two pregnancies (PP). e, Sample M-mode echocardiograms of PP
HKO mice, and control mice containing the αMHC-Cre transgene alone (PP CRE). f–i,
Echocardiographic measures in mice of the indicated genotypes, either nulliparous or post-
partum (PP). n≥5 for all groups. *p<0.05
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tFigure 2. PGC-1α regulates an angiogenic program in cardiomyocytes
a–b, Relative expression of mitochondrial genes (cycs and cox5b) and angiogenic genes
(vegfa, pdgfb, bfgf) in neonatal rat ventricular myocytes (NRVMs) infected with adenovirus
expressing PGC-1α versus GFP (a), or siPGC-1α versus siCtrl (b). c–d, PGC-1α expression
in NRVMs induces the migration of adjacent endothelial cells, and the migration is blocked
by sFlt1. Representative images (c) show phalloidin-stained endothelial cells that have
migrated towards the NRVMs. Experimental procedure is schematized in bottom panel.
Data are quantified in (d). e, Knockdown of PGC-1α inhibits the migration of endothelial
cells. Error bars are +/− SE. *p<0.05 versus control. †p<0.05 versus cells not treated with
sFlt1.
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tFigure 3. Mice lacking cardiac PGC-1α have reduced microvascular density that is worsened by
pregnancy
a–b, Relative mRNA expression of the indicated genes (a) and VEGF protein levels (b) in
HKO versus control hearts. c–d, Vascular density in hearts from CT and HKO mice
nulliparous or post-partum (PP). Representative images stained for CD31 (PECAM) are
shown in c, and quantified in d. e–f, Reduced cardiac MIBI uptake in PP HKO versus PP
CT animals. Representative SPECT/CT images are shown in f, and quantified in e. n≥5 for
all groups. Error bars are +/− SE. *p<0.05 versus control.
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tFigure 4. Combined treatment with VEGF and Bromocriptine rescues PPCM in PGC-1α HKO
mice
a, Schema of proposed role of cardiac PGC-1α in the regulation of cardiac angiogenesis,
and defending against pregnancy-induced anti-angiogenic factors. b, Experimental outline.
c, Sample echocardiograms from PP HKO, PP CRE, and PP HKO mice receiving both
bromocriptine and VEGF treatments (PP HKO + Br/VEGF). d–h, Indicated
echocardiographic measures (d–f), heart weight (g), and heart weight/tibial length ratio (h),
in post-partum mice of the indicated genotypes. n≥5 for all groups. Error bars are +/− SE.
*p<0.05 versus PP CRE control. †p<0.05 versus PP HKO.
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tFigure 5. Women with pre-eclampsia have depressed cardiac function that correlates with
circulating sFlt1 levels, and sFlt1 causes cardiac dysfunction in mice
a, Sample tracing of tissue Doppler imaging. MPI: myocardial performance index. IVCT:
isovolemic contraction time. IVRT: isovolemic relaxation time. b–c, Elevated MPI (b) and
E/E′ (c) in women with pre-eclampsia (PE) versus normal (NL) pregnancies. p=0.01 and
p=0.02, respectively. d, Elevated MPI correlates with sFlt1 levels. R=.59. p=0.003. e,
Elevated MPI in pregnant mice infected with adenovirus expressing sFlt1. p=0.01 n≥5 for all
groups. *p<0.05 versus control.
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tFigure 6. sFlt1 is sufficient to induce cardiomyopathy in HKO mice, women with PPCM have
elevated sFlt1 levels, and pre-eclampsia as a risk factor for PPCM
a–c, Heart weight/tibial length ratios (a), echocardiographic fractional shortening (b), and
LV end-systolic dimensions (c) in HKO mice injected with adenovirus expressing sFlt1,
versus controls. d, Elevated sFlt1 levels in post-partum women with PPCM. p=0.002. e–f,
Prevalence of pre-eclampsia among all deliveries (e) and among women with PPCM (f) at
Harvard teaching hospitals in the previous 9 years.
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